Harrow, Inc. Share-based Payment Arrangement, Expense
Harrow, Inc. (HROW) reported Share-based Payment Arrangement, Expense of $12.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-02
- Harrow, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $3.80M, a 20.71% decline year-over-year.
- Harrow, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $3.27M, a 25.43% decline year-over-year.
- Harrow, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $875.00K, a 79.51% decline year-over-year.
- Harrow, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $4.56M, a 9.28% increase year-over-year.
- Harrow, Inc. share-based payment arrangement, expense for fiscal 2025 was $12.50M, a 29.04% decline from fiscal 2024.
- Harrow, Inc. share-based payment arrangement, expense for fiscal 2024 was $17.62M, a 12.25% increase from fiscal 2023.
- Harrow, Inc. share-based payment arrangement, expense for fiscal 2023 was $15.70M, a 96.84% increase from fiscal 2022.
- Harrow, Inc. share-based payment arrangement, expense for fiscal 2022 was $7.97M, a 38.80% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed | Share-based Payment Arrangement, Expense 173 month | Share-based Payment Arrangement, Expense 185 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $7.07M derived: sum of 2 quarters · filed 2026-03-02 | $7.95M derived: sum of 3 quarters · filed 2026-03-02 | $12.50M 10-K · filed 2026-03-02 | ||||||
| 2025-09-30 | $3.27M 10-Q · filed 2025-11-10 | $4.14M derived: sum of 2 quarters · filed 2025-11-10 | $8.70M 10-Q · filed 2025-11-10 | $13.49M derived: sum of 4 quarters · filed 2026-03-02 | ||||||
| 2025-06-30 | $875.00K 10-Q · filed 2025-08-11 | $5.43M 10-Q · filed 2025-08-11 | $10.22M derived: sum of 3 quarters · filed 2026-03-02 | $14.61M derived: sum of 4 quarters · filed 2026-03-02 | ||||||
| 2025-03-31 | $4.56M 10-Q · filed 2025-05-08 | $9.35M derived: sum of 2 quarters · filed 2026-03-02 | $13.73M derived: sum of 3 quarters · filed 2026-03-02 | $18.01M derived: sum of 4 quarters · filed 2026-03-02 | ||||||
| 2024-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.18M derived: sum of 2 quarters · filed 2026-03-02 | $13.45M derived: sum of 3 quarters · filed 2026-03-02 | $17.62M 10-K · filed 2026-03-02 | ||||||
| 2024-09-30 | $4.38M 10-Q · filed 2025-11-10 | $8.66M derived: sum of 2 quarters · filed 2025-11-10 | $12.82M 10-Q · filed 2025-11-10 | $17.00M derived: sum of 4 quarters · filed 2026-03-02 | ||||||
| 2024-06-30 | $4.27M 10-Q · filed 2025-08-11 | $8.44M 10-Q · filed 2025-08-11 | $12.62M derived: sum of 3 quarters · filed 2026-03-02 | $17.09M derived: sum of 4 quarters · filed 2026-03-02 | ||||||
| 2024-03-31 | $4.17M 10-Q · filed 2025-05-08 | $8.34M derived: sum of 2 quarters · filed 2026-03-02 | $12.82M derived: sum of 3 quarters · filed 2026-03-02 | $18.23M derived: sum of 4 quarters · filed 2026-03-02 | ||||||
| 2023-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.65M derived: sum of 2 quarters · filed 2026-03-02 | $14.06M derived: sum of 3 quarters · filed 2026-03-02 | $15.70M 10-K · filed 2026-03-02 | ||||||
| 2023-09-30 | $4.48M 10-Q · filed 2024-11-14 | $9.89M derived: sum of 2 quarters · filed 2024-11-14 | $11.52M 10-Q · filed 2024-11-14 | $13.55M derived: sum of 4 quarters · filed 2024-11-14 | ||||||
| 2023-06-30 | $5.41M 10-Q · filed 2024-08-07 | $7.04M 10-Q · filed 2024-08-07 | $9.08M derived: sum of 3 quarters · filed 2024-08-07 | $11.01M derived: sum of 4 quarters · filed 2024-08-07 | ||||||
| 2023-03-31 | $1.63M 10-Q · filed 2024-05-13 | $3.67M derived: sum of 2 quarters · filed 2024-05-13 | $5.60M derived: sum of 3 quarters · filed 2024-05-13 | $7.59M derived: sum of 4 quarters · filed 2024-05-13 | ||||||
| 2022-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.96M derived: sum of 2 quarters · filed 2024-03-19 | $5.96M derived: sum of 3 quarters · filed 2024-03-19 | $7.97M 10-K · filed 2024-03-19 | ||||||
| 2022-09-30 | $1.93M 10-Q · filed 2023-11-13 | $3.92M derived: sum of 2 quarters · filed 2023-11-13 | $5.94M 10-Q · filed 2023-11-13 | $8.06M derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | $1.99M 10-Q · filed 2023-08-09 | $4.01M 10-Q · filed 2023-08-09 | $6.12M derived: sum of 3 quarters · filed 2023-08-09 | $7.82M derived: sum of 4 quarters · filed 2023-08-09 | ||||||
| 2022-03-31 | $2.02M 10-Q · filed 2023-05-11 | $4.13M derived: sum of 2 quarters · filed 2023-05-11 | $5.83M derived: sum of 3 quarters · filed 2023-05-11 | $6.91M derived: sum of 4 quarters · filed 2023-05-11 | ||||||
| 2021-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $3.81M derived: sum of 2 quarters · filed 2023-03-23 | $4.89M derived: sum of 3 quarters · filed 2023-03-23 | $5.75M 10-K · filed 2023-03-23 | ||||||
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-14 | $2.77M derived: sum of 2 quarters · filed 2022-11-14 | $3.63M 10-Q · filed 2022-11-14 | $4.41M derived: sum of 4 quarters · filed 2022-11-14 | ||||||
| 2021-06-30 | $1.08M 10-Q · filed 2022-08-09 | $1.93M 10-Q · filed 2022-08-09 | $2.71M derived: sum of 3 quarters · filed 2022-08-09 | $3.63M derived: sum of 4 quarters · filed 2022-08-09 | ||||||
| 2021-03-31 | $855.00K 10-Q · filed 2022-05-05 | $1.64M derived: sum of 2 quarters · filed 2022-05-05 | $2.55M derived: sum of 3 quarters · filed 2022-05-05 | $3.18M derived: sum of 4 quarters · filed 2022-05-05 | ||||||
| 2020-12-31 | $780.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.70M derived: sum of 2 quarters · filed 2022-03-10 | $2.33M derived: sum of 3 quarters · filed 2022-03-10 | $2.86M 10-K · filed 2022-03-10 | ||||||
| 2020-09-30 | $917.00K 10-Q · filed 2021-11-09 | $1.54M derived: sum of 2 quarters · filed 2021-11-09 | $2.08M 10-Q · filed 2021-11-09 | $2.54M derived: sum of 4 quarters · filed 2021-11-09 | ||||||
| 2020-06-30 | $628.00K 10-Q · filed 2021-08-10 | $1.16M 10-Q · filed 2021-08-10 | $1.63M derived: sum of 3 quarters · filed 2021-08-10 | $2.03M derived: sum of 4 quarters · filed 2021-08-10 | ||||||
| 2020-03-31 | $533.00K 10-Q · filed 2021-05-11 | $998.00K derived: sum of 2 quarters · filed 2021-05-11 | $1.40M derived: sum of 3 quarters · filed 2021-05-11 | $1.77M derived: sum of 4 quarters · filed 2021-05-11 | ||||||
| 2019-12-31 | $465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $868.00K derived: sum of 2 quarters · filed 2021-03-08 | $1.24M derived: sum of 3 quarters · filed 2021-03-08 | $2.02M 10-K · filed 2021-03-08 | ||||||
| 2019-09-30 | $403.00K 10-Q · filed 2020-11-09 | $770.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.56M 10-Q · filed 2020-11-09 | $2.14M derived: sum of 4 quarters · filed 2020-11-09 | ||||||
| 2019-06-30 | $367.00K 10-Q · filed 2020-08-10 | $1.16M 10-Q · filed 2020-08-10 | $1.73M derived: sum of 3 quarters · filed 2020-08-10 | $2.33M derived: sum of 4 quarters · filed 2020-08-10 | ||||||
| 2019-03-31 | $788.00K 10-Q · filed 2020-05-11 | $1.37M derived: sum of 2 quarters · filed 2020-05-11 | $1.97M derived: sum of 3 quarters · filed 2020-05-11 | $2.58M derived: sum of 4 quarters · filed 2020-05-11 | ||||||
| 2018-12-31 | $578.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $1.18M derived: sum of 2 quarters · filed 2020-03-13 | $1.79M derived: sum of 3 quarters · filed 2020-03-13 | $2.64M 10-K · filed 2020-03-13 | ||||||
| 2018-09-30 | $602.00K 10-Q · filed 2019-11-13 | $1.21M derived: sum of 2 quarters · filed 2019-11-13 | $2.06M 10-Q · filed 2019-11-13 | $2.64M derived: sum of 4 quarters · filed 2019-11-13 | ||||||
| 2018-06-30 | $608.00K 10-Q · filed 2019-08-14 | $1.36M 10-Q · filed 2019-08-14 | $2.04M derived: sum of 3 quarters · filed 2019-08-14 | $2.69M derived: sum of 4 quarters · filed 2019-08-14 | ||||||
| 2018-03-31 | $751.00K 10-Q · filed 2019-05-09 | $1.43M derived: sum of 2 quarters · filed 2019-05-09 | $2.08M derived: sum of 3 quarters · filed 2019-05-09 | $2.74M derived: sum of 4 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.33M derived: sum of 2 quarters · filed 2019-03-12 | $1.99M derived: sum of 3 quarters · filed 2019-03-12 | $2.94M 10-K · filed 2019-03-12 | ||||||
| 2017-09-30 | $648.00K 10-Q · filed 2018-11-13 | $1.31M derived: sum of 2 quarters · filed 2018-11-13 | $2.27M 10-Q · filed 2018-11-13 | $2.95M derived: sum of 4 quarters · filed 2018-11-13 | ||||||
| 2017-06-30 | $667.00K 10-Q · filed 2018-08-06 | $1.62M 10-Q · filed 2018-08-06 | $2.30M derived: sum of 3 quarters · filed 2018-08-06 | $3.18M derived: sum of 4 quarters · filed 2018-08-06 | ||||||
| 2017-03-31 | $950.00K 10-Q · filed 2018-05-15 | $1.63M derived: sum of 2 quarters · filed 2018-05-15 | $2.51M derived: sum of 3 quarters · filed 2018-05-15 | $3.67M derived: sum of 4 quarters · filed 2018-05-15 | ||||||
| 2016-12-31 | $684.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.56M derived: sum of 2 quarters · filed 2018-03-08 | $2.72M derived: sum of 3 quarters · filed 2018-03-08 | $3.79M 10-K · filed 2018-03-08 | ||||||
| 2016-09-30 | $879.00K 10-Q · filed 2017-11-14 | $2.04M derived: sum of 2 quarters · filed 2017-11-14 | $3.10M 10-Q · filed 2017-11-14 | $4.23M derived: sum of 4 quarters · filed 2017-11-14 | ||||||
| 2016-06-30 | $1.16M 10-Q · filed 2017-08-10 | $2.23M 10-Q · filed 2017-08-10 | $3.35M derived: sum of 3 quarters · filed 2017-08-10 | $4.30M derived: sum of 4 quarters · filed 2017-08-10 | ||||||
| 2016-03-31 | $1.06M 10-Q · filed 2017-05-10 | $2.19M derived: sum of 2 quarters · filed 2017-05-10 | $3.14M derived: sum of 3 quarters · filed 2017-05-10 | $3.85M derived: sum of 4 quarters · filed 2017-05-10 | ||||||
| 2015-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $2.08M derived: sum of 2 quarters · filed 2017-03-21 | $2.78M derived: sum of 3 quarters · filed 2017-03-21 | $3.44M 10-K · filed 2017-03-21 | ||||||
| 2015-09-30 | $956.00K 10-Q · filed 2016-11-14 | $1.66M derived: sum of 2 quarters · filed 2016-11-14 | $2.32M 10-Q · filed 2016-11-14 | $2.98M derived: sum of 4 quarters · filed 2016-11-14 | ||||||
| 2015-06-30 | $703.00K 10-Q · filed 2016-08-15 | $1.36M 10-Q · filed 2016-08-15 | $2.02M derived: sum of 3 quarters · filed 2016-08-15 | $2.58M derived: sum of 4 quarters · filed 2016-08-15 | ||||||
| 2015-03-31 | $658.00K 10-Q · filed 2016-05-12 | $1.32M derived: sum of 2 quarters · filed 2016-05-12 | $1.88M derived: sum of 3 quarters · filed 2016-05-12 | $2.54M derived: sum of 4 quarters · filed 2016-05-12 | ||||||
| 2014-12-31 | $664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $1.22M derived: sum of 2 quarters · filed 2016-03-23 | $1.88M derived: sum of 3 quarters · filed 2016-03-23 | $2.56M 10-K · filed 2016-03-23 | $2.56M 10-K · filed 2015-03-12 | |||||
| 2014-09-30 | $555.00K 10-Q · filed 2015-11-12 | $554.64K 10-Q · filed 2014-11-12 | $1.21M derived: sum of 2 quarters · filed 2015-11-12 | $1.90M 10-Q · filed 2015-11-12 | $1.90M 10-Q · filed 2014-11-12 | $2.71M derived: sum of 4 quarters · filed 2015-11-12 | ||||
| 2014-06-30 | $659.00K 10-Q · filed 2015-08-12 | $658.75K 10-Q · filed 2014-08-13 | $1.35M 10-Q · filed 2015-08-12 | $1.35M 10-Q · filed 2014-08-13 | $2.16M derived: sum of 3 quarters · filed 2015-08-12 | $3.03M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2014-03-31 | $688.00K 10-Q · filed 2015-05-13 | $687.94K 10-Q · filed 2014-05-15 | $1.50M derived: sum of 2 quarters · filed 2015-05-13 | $2.37M derived: sum of 3 quarters · filed 2015-05-13 | $3.37M derived: sum of 4 quarters · filed 2015-05-13 | |||||
| 2013-12-31 | $808.01K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $1.69M derived: sum of 2 quarters · filed 2015-03-12 | $2.68M derived: sum of 3 quarters · filed 2015-03-12 | $3.13M 10-K · filed 2015-03-12 | $8.23M 10-K · filed 2014-03-28 | |||||
| 2013-09-30 | $878.58K 10-Q · filed 2014-11-12 | $1.87M derived: sum of 2 quarters · filed 2014-11-12 | $2.33M 10-Q · filed 2014-11-12 | $2.94M derived: sum of 4 quarters · filed 2014-11-12 | ||||||
| 2013-06-30 | $995.14K 10-Q · filed 2014-08-13 | $1.45M 10-Q · filed 2014-08-13 | $2.06M derived: sum of 3 quarters · filed 2014-08-13 | $2.71M derived: sum of 4 quarters · filed 2014-08-13 | ||||||
| 2013-03-31 | $410.71K 10-Q · filed 2014-05-15 | $1.07M derived: sum of 2 quarters · filed 2014-05-15 | $1.72M derived: sum of 3 quarters · filed 2014-05-15 | $2.45M derived: sum of 4 quarters · filed 2014-05-15 | ||||||
| 2012-12-31 | $654.53K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $1.31M derived: sum of 2 quarters · filed 2014-03-28 | $2.04M derived: sum of 3 quarters · filed 2014-03-28 | $2.16M 10-K · filed 2014-03-28 | $5.09M 10-K · filed 2013-03-18 | |||||
| 2012-09-30 | $654.04K 10-Q · filed 2013-11-06 | $1.38M derived: sum of 2 quarters · filed 2013-11-06 | $1.50M 10-Q · filed 2013-11-06 | |||||||
| 2012-06-30 | $729.53K 10-Q · filed 2013-08-14 | $848.04K 10-Q · filed 2013-08-14 | ||||||||
| 2012-03-31 | $118.50K 10-Q · filed 2013-05-08 | |||||||||
| 2011-12-31 | $192.15K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |